Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration
Por:
Mendieta, G, Ben-Aicha, S, Gutierrez, M, Casani, L, Arzanauskait, M, Carreras, F, Sabate, M, Badimon, L, Vilahur, G
Publicada:
31 mar 2020
Resumen:
BACKGROUND Beyond lipid-towering, statins exert cardioprotective effects. High-dose statin treatment seems to reduce cardiovascular complications in high-risk patients. The ideal timing and administration regime remain unknown.
OBJECTIVES This study compared the cardioprotective effects of intravenous statin administration during myocardial infarction (MI) with oral administration immediately post-MI.
METHODS Hypercholesterolemic pigs underwent MI induction (90 min of ischemia) and were kept for 42 days. Animals were distributed in 3 arms (A): A1 received an intravenous bolus of atorvastatin during MI; A2 received an intravenous bolus of vehicle during MI; and A3 received oral atorvastatin within 2 h post-Mt A1 and A3 remained on daily oral atorvastatin for the following 42 days. Cardiac magnetic resonance analysis (days 3 and 42 post-MI) and molecular/histological studies were performed.
RESULTS At day 3, A1 showed a 10% reduction in infarct size compared with A3 and A2 and a 50% increase in myocardial salvage. At day 42, both A1 and A3 showed a significant decrease in scar size versus A2; however, A1 showed a further 24% reduction versus A3. Functional analyses revealed improved systolic performance in A1 compared with A2 and less wall motion abnormalities in the jeopardized myocardium versus both groups at day 42. A1 showed enhanced collagen content and AMP-activated protein kinase activation in the scar, increased vessel density in the penumbra, higher tumor necrosis factor alpha plasma levels and tower peripheral blood mononuclear cell activation versus both groups.
CONCLUSIONS Intravenous administration of atorvastatin during MI limits cardiac damage, improves cardiac function, and mitigates remodeling to a larger extent than when administered orally shortly after reperfusion. This therapeutic approach deserves to be investigated in ST-segment elevation MI patients. (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
Filiaciones:
Mendieta, G:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Clin Hosp, Dept Cardiol, Barcelona, Spain
Ben-Aicha, S:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Gutierrez, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Radiol, Barcelona, Spain
Casani, L:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Hosp Santa Creu & Sant Pau, IIB St Pau, Radiol, Barcelona, Spain
Arzanauskait, M:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Carreras, F:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiol, Barcelona, Spain
Sabate, M:
Clin Hosp, Dept Cardiol, Barcelona, Spain
Badimon, L:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Inst Carlos III, CiberCV, Barcelona, Spain
Vilahur, G:
Hosp Santa Creu & Sant Pau, IIB St Pau, Cardiovasc Res Ctr ICCC, Barcelona, Spain
Inst Carlos III, CiberCV, Barcelona, Spain
Hybrid Gold
|